Pathogenesis of pediatric multiple sclerosis

Journal of Child Neurology

Volumn 27, Issue 11, 2012, Pages 1394-1407

  Vargas Lowy, David ^a   Chitnis, Tanuja ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

demyelination; multiple sclerosis; pathogenesis

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 17; VITAMIN D; VITAMIN D RECEPTOR;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ANTIBODY RESPONSE; B LYMPHOCYTE; BRAIN DAMAGE; BRAIN INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CHILDHOOD DISEASE; DEMYELINATION; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOPATHOGENESIS; MENINGITIS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; T LYMPHOCYTE; TH17 CELL; VITAMIN BLOOD LEVEL; VITAMIN METABOLISM;

AGE OF ONSET; ANIMALS; CAUSALITY; CHILD; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; RISK FACTORS; SEX DISTRIBUTION;

EID: 84867716060     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073812456084     Document Type: Review

References (170)

1. Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler. 2009 ; 15: 627-631
2. Boiko A, Vorobeychik G, Paty D, et al. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002 ; 59: 1006-1010
3. Ghezzi A, Deplano V, Faroni J, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler. 1997 ; 3: 43-46
4. Sindern E, Haas J, Stark E, Wurster U. Early onset MS under the age of 16: clinical and paraclinical features. Acta Neurol Scand. 1992 ; 86: 280-284
5. Banwell B, Kennedy J, Sadovnick D, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2009 ; 72: 232-239
6. Pohl D, Hennemuth I, von Kries R, Hanefeld F. Paediatric multiple sclerosis and acute disseminated encephalomyelitis in Germany: results of a nationwide survey. Eur J Pediatr. 2007 ; 166: 405-412
7. Langer-Gould A, Zhang JL, Chung J, et al. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology. 2011 ; 77: 1143-1148
8. Banwell B, Bar-Or A, Arnold DL, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol. 2011 ; 10: 436-445
9. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009 ; 66: 54-59
10. Yeh EA, Weinstock-Guttman B, Ramanathan M, et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain. 2009 ; 132 (pt 12). 3392-3400
11. Waubant E, Chabas D, Okuda DT, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. 2009 ; 66: 967-971
12. Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology. 2008 ; 70: 1891-1897
13. MacAllister WS, Belman AL, Milazzo M, et al. Cognitive functioning in children and adolescents with multiple sclerosis. Neurology. 2005 ; 64: 1422-1425
14. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007 ; 356: 2603-2613
15. Simone IL, Carrara D, Tortorella C, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology. 2002 ; 59: 1922-1928
16. Trojano M, Paolicelli D, Bellacosa A, et al. Atypical forms of multiple sclerosis or different phases of a same disease?. Neurol Sci. 2004 ; 25 (suppl 4). S323 - S325
17. Prineas JW, Wright RG. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest. 1978 ; 38: 409-421
18. Prineas JW, Raine CS. Electron microscopy and immunoperoxidase studies of early multiple sclerosis lesions. Neurology. 1976 ; 26 ((6 pt 2)). 29-32
19. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 ;: 338278-285
20. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000 ; 47: 707-717
21. Ishizu T, Osoegawa M, Mei FJ, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain. 2005 ; 128 (pt 5). 988-1002
22. Vishwas MS, Chitnis T, Pienaar R, et al. Tract-based analysis of callosal, projection, and association pathways in pediatric patients with multiple sclerosis: a preliminary study. AJNR Am J Neuroradiol. 2010 ; 31: 121-128
23. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005 ; 128 (pt 11). 2705-2712
24. Kutzelnigg A, Faber-Rod JC, Bauer J, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 2007 ; 17: 38-44
25. Absinta M, Rocca MA, Moiola L, et al. Cortical lesions in children with multiple sclerosis. Neurology. 2011 ; 76: 910-913
26. Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011 ; 134 (pt 9). 2755-2771
27. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007 ; 130 (pt 4). 1089-1104
28. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004 ; 14: 164-174
29. Itoh T, Shimizu M, Kitami K, et al. Primary extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type in the CNS. Neuropathology. 2001 ; 21: 174-180
30. Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006 ; 116: 3183-3194
31. Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007 ; 204: 2899-2912
32. Lassmann H, Niedobitek G, Aloisi F, Middeldorp JM. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue-report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain. 2011 ; 134 (pt 9). 2772-2786
33. Aloisi F, Serafini B, Magliozzi R, et al. Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. Brain. 2010 ; 133 (pt 12). e157
34. Willis SN, Stadelmann C, Rodig SJ, et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009 ; 132 (pt 12). 3318-3328
35. Anderson RC, Connolly ES, Komotar RJ, et al. Clinicopathological review: tumefactive demyelination in a 12-year-old girl. Neurosurgery. 2005 56: 1051-1057
36. Dastgir J, DiMario FJ. Acute tumefactive demyelinating lesions in a pediatric patient with known diagnosis of multiple sclerosis: review of the literature and treatment proposal. J Child Neurol. 2009 ; 24: 431-437
37. McAdam LC, Blaser SI, Banwell BL. Pediatric tumefactive demyelination: case series and review of the literature. Pediatr Neurol. 2002 ; 26: 18-25
38. Riva D, Chiapparini L, Pollo B, et al. A case of pediatric tumefactive demyelinating lesion misdiagnosed and treated as glioblastoma. J Child Neurol. 2008 ; 23: 944-947
39. Vanlandingham M, Hanigan W, Vedanarayanan V, Fratkin J. An uncommon illness with a rare presentation: neurosurgical management of ADEM with tumefactive demyelination in children. Childs Nerv Syst. 2010 ; 26: 655-661
40. Tenembaum S, Chitnis T, Ness J, Hahn JS. Acute disseminated encephalomyelitis. Neurology. 2007 ; 68 (16 suppl 2). S23 - S36
41. Banwell B, Krupp L, Kennedy J, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 2007 ; 6: 773-781
42. Young NP, Weinshenker BG, Parisi JE, et al. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain. 133 (Pt 2). 333-348
43. Inglese M, Salvi F, Iannucci G, et al. Magnetization transfer and diffusion tensor MR imaging of acute disseminated encephalomyelitis. AJNR Am J Neuroradiol. 2002 ; 23: 267-272
44. Vishwas MS, Healy BC, Pienaar R, et al. Diffusion tensor analysis of pediatric multiple sclerosis and clinically isolated syndromes. Am J Neuroradiol. :
45. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria.". Ann Neurol. 2005 ; 58: 840-846
46. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2005 ; 62: 865-870
47. Tintore M, Rovira A, Brieva L, et al. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Mult Scler. 2001 ; 7: 359-363
48. Ghezzi A, Pozzilli C, Liguori M, et al. Prospective study of multiple sclerosis with early onset. Mult Scler. 2002 ; 8: 115-118
49. Ruggieri M, Polizzi A, Pavone L, Grimaldi LM. Multiple sclerosis in children under 6 years of age. Neurology. 1999 ; 53: 478-484
50. Pohl D, Rostasy K, Reiber H, Hanefeld F. CSF characteristics in early-onset multiple sclerosis. Neurology. 2004 ; 63: 1966-1967
51. Hanefeld F, Bauer HJ, Christen HJ, et al. Multiple sclerosis in childhood: report of 15 cases. Brain Dev. 1991 ; 13: 410-416
52. Riikonen R. The role of infection and vaccination in the genesis of optic neuritis and multiple sclerosis in children. Acta Neurol Scand. 1989 ; 80: 425-431
53. Atzori M, Battistella PA, Perini P, et al. Clinical and diagnostic aspects of multiple sclerosis and acute monophasic encephalomyelitis in pediatric patients: a single centre prospective study. Mult Scler. 2009 ; 15: 363-370
54. Dale RC, de Sousa C, Chong WK, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000 ; 123 (pt 12). 2407-2422
55. Hynson JL, Kornberg AJ, Coleman LT, et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology. 2001 ; 56: 1308-1312
56. Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology. 2002 ; 59: 1224-1231
57. Mikaeloff Y, Suissa S, Vallee L, et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr. 2004 ; 144: 246-252
58. Chabas D, Ness J, Belman A, et al. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology. 2010 ; 74: 399-405
59. Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol. 2007 ; 79: 43-72
60. Markovic-Plese S, Cortese I, Wandinger KP, et al. CD4+CD28- costimulation-independent T cells in multiple sclerosis. J Clin Invest. 2001 ; 108: 1185-1194
61. Zhang J, Markovic-Plese S, Lacet B, et al. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1994 ; 179: 973-984
62. Bar-Or A. The immunology of multiple sclerosis. Semin Neurol. 2008 ; 28: 29-45
63. Chitnis T, Khoury SJ. Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis. Immunol Res. 2003 ; 28: 223-239
64. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone, I: Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986 ; 136: 2348-2357
65. Balashov KE, Smith DR, Khoury SJ, et al. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A. 1997 ; 94: 599-603
66. Comabella M, Balashov K, Issazadeh S, et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest. 1998 ; 102: 671-678
67. Beck J, Rondot P, Catinot L, et al. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?. Acta Neurol Scand. 1988 ; 78: 318-323
68. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009 ; 27: 485-517
69. Stromnes IM, Cerretti LM, Liggitt D, et al. Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells. Nat Med. 2008 ; 14: 337-342
70. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002 ; 8: 500-508
71. Matusevicius D, Kivisakk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler. 1999 ; 5: 101-104
72. Graber JJ, Allie SR, Mullen KM, et al. Interleukin-17 in transverse myelitis and multiple sclerosis. J Neuroimmunol. 2008 ; 196: 124-132
73. Frisullo G, Nociti V, Iorio R, et al. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine. 2008 ; 44: 22-25
74. Brucklacher-Waldert V, Stuerner K, Kolster M, et al. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain. 2009 ; 132 (pt 12). 3329-3341
75. Ifergan I, Kebir H, Bernard M, et al. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain. 2008 ; 131 (pt 3). 785-799
76. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007 ; 13: 1173-1175
77. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004 ; 199: 971-979
78. Crucian B, Dunne P, Friedman H, et al. Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. Clin Diagn Lab Immunol. 1995 ; 2: 249-252
79. Karaszewski JW, Reder AT, Anlar B, et al. Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. Ann Neurol. 1991 ; 30: 42-47
80. Correale J, Gilmore W, McMillan M, et al. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol. 1995 ; 154: 2959-2968
81. Pelfrey CM, Rudick RA, Cotleur AC, et al. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J Immunol. 2000 ; 165: 1641-1651
82. Fukaura H, Kent SC, Pietrusewicz MJ, et al. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest. 1996 ; 98: 70-77
83. Chitnis T, Imitola J, Khoury SJ. Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis. Curr Drug Targets Immune Endocr Metabol Disord. 2005 ; 5: 11-26
84. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann Neurol. 2009 ; 65: 239-248
85. Taub DD, Longo DL. Insights into thymic aging and regeneration. Immunol Rev. 2005 ; 205: 72-93
86. Cossarizza A, Ortolani C, Paganelli R, et al. CD45 isoforms expression on CD4+ and CD8+ T cells throughout life, from newborns to centenarians: implications for T cell memory. Mech Ageing Dev. 1996 ; 86: 173-195
87. Castle SC, Uyemura K, Crawford W, et al. Age-related impaired proliferation of peripheral blood mononuclear cells is associated with an increase in both IL-10 and IL-12. Exp Gerontol. 1999 ; 34: 243-252
88. Weksler ME. Changes in the B-cell repertoire with age. Vaccine. 2000 ; 18: 1624-1628
89. Vallejo AN. Age-dependent alterations of the T cell repertoire and functional diversity of T cells of the aged. Immunol Res. 2006 ; 36: 221-228
90. Goronzy JJ, Lee WW, Weyand CM. Aging and T-cell diversity. Exp Gerontol. 2007 ; 42: 400-406
91. Gorczynski RM, Kennedy M, MacRae S.. Altered lymphocyte recognition repertoire during ageing, III: Changes in MHC restriction patterns in parental T lymphocytes and diminution in T suppressor function. Immunology. 1984 ; 52: 611-620
92. Faria AM, de Moraes SM, de Freitas LH, et al. Variation rhythms of lymphocyte subsets during healthy aging. Neuroimmunomodulation. 2008 ; 15: 365-379
93. Simone R, Zicca A, Saverino D. The frequency of regulatory CD3+CD8+CD28- CD25+ T lymphocytes in human peripheral blood increases with age. J Leukoc Biol. 2008 ; 84: 1454-1461
94. Chitnis T, Khoury SJ.. Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. J Allergy Clin Immunol. 2003 ; 112: 837-849
95. Costantino CM, Baecher-Allan C, Hafler DA. Multiple sclerosis and regulatory T cells. J Clin Immunol. 2008 ; 28: 697-706
96. Banwell B, Bar-Or A, Cheung R, et al. Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann Neurol. 2008 ; 63: 98-111
97. Correale J, Tenembaum SN. Myelin basic protein and myelin oligodendrocyte glycoprotein T-cell repertoire in childhood and juvenile multiple sclerosis. Mult Scler. 2006 ; 12: 412-420
98. Antel JP, Bar-Or A. Do myelin-directed antibodies predict multiple sclerosis?. N Engl J Med. 2003 ; 349: 107-109
99. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med. 2006 ; 354: 942-955
100. Owens GP, Bennett JL, Lassmann H, et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol. 2009 ; 65: 639-649
101. O'Connor KC, Chitnis T, Griffin DE, et al. Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol. 2003 ; 136: 140-148
102. O'Connor KC, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007 ; 13: 211-217
103. Cross AH, Trotter JL, Lyons J. B cells and antibodies in CNS demyelinating disease. J Neuroimmunol. 2001 ; 112: 1-14
104. Antel J, Bar-Or A. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment. J Neuroimmunol. 2006 ; 180: 3-8
105. McLaughlin KA, Chitnis T, Newcombe J, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol. 2009 ; 183: 4067-4076
106. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol. 2009 ; 66: 833-842
107. Di Pauli F, Mader S, Rostasy K, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol. 2011 ; 138: 247-254
108. Probstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 2011 ; 77: 580-588
109. Bettelli E, Baeten D, Jager A, et al. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest. 2006 ; 116: 2393-2402
110. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J Clin Invest. 2006 ; 116: 2385-2392
111. Moscarello MA, Mastronardi FG, Wood DD. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res. 2007 ; 32: 251-256
112. O'Connor KC, Lopez-Amaya C, Gagne D, et al. Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. J Neuroimmunol. 2010 ; 223: 92-99
113. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008 ; 358: 676-688
114. Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006 ; 180: 63-70
115. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol. 2007 ; 178: 6092-6099
116. Youinou P, Jamin C, Pers JO, et al. B lymphocytes are required for development and treatment of autoimmune diseases. Ann N YAcad Sci. 2005 ; 1050: 19-33
117. Rovaris M, Gallo A, Falini A, et al. Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. Arch Neurol. 2005 ; 62: 898-902
118. Rostasy K, Withut E, Pohl D, et al. Tau, phospho-tau, and S-100B in the cerebrospinal fluid of children with multiple sclerosis. J Child Neurol. 2005 ; 20: 822-825
119. Dhaunchak AS, Becker C, Schulman H, et al. Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis. Ann Neurol. 2012 ; 71: 601-613
120. Stewart GJ, McLeod JG, Basten A, Bashir HV. HLA family studies and multiple sclerosis: a common gene, dominantly expressed. Hum Immunol. 1981 ; 3: 13-29
121. Haines JL, Terwedow HA, Burgess K, et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. the Multiple Sclerosis Genetics Group. Hum Mol Genet. 1998 ; 7: 1229-1234
122. Sawcer S, Goodfellow PN. Inheritance of susceptibility to multiple sclerosis. Curr Opin Immunol. 1998 ; 10: 697-703
123. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007 ; 357: 851-862
124. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009 ; 66: 54-59
125. Kennedy J, O'Connor P, Sadovnick AD, et al. Age at onset of multiple sclerosis may be influenced by place of residence during childhood rather than ancestry. Neuroepidemiology. 2006 ; 26: 162-167
126. Disanto G, Magalhaes S, Handel AE, et al. HLA-DRB1 confers increased risk of pediatric-onset MS in children with acquired demyelination. Neurology. 2011 ; 76: 781-786
127. Ohlenbusch A, Pohl D, Hanefeld F. Myelin oligodendrocyte gene polymorphisms and childhood multiple sclerosis. Pediatr Res. 2002 ; 52: 175-179
128. Anlar B, Alikasifoglu M, Kose G, et al. Tumor necrosis factor-alpha gene polymorphisms in children with multiple sclerosis. Neuropediatrics. 2001 ; 32: 214-216
129. Chitnis T, Krupp L, Yeh A, et al. Pediatric multiple sclerosis. Neurol Clin. 2011 ; 29: 481-505
130. Bar-Or A, Smith D Principles of Neuroepidemiology. Batchelor T and Cudcowicz M, ed. Boston, MA: Butterworth-Heinemann ; 2001 :
131. Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog Neurobiol. 1995 ; 47: 425-448
132. Alotaibi S, Kennedy J, Tellier R, et al. Epstein-Barr virus in pediatric multiple sclerosis. J Am Med Assoc. 2004 ; 291: 1875-1879
133. Ascherio A, Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol. 2008 ; 28: 17-28
134. Lunemann JD, Huppke P, Roberts S, et al. Broadened and elevated humoral immune response to EBNA1 in pediatric multiple sclerosis. Neurology. 2008 ; 71: 1033-1035
135. Pohl D, Krone B, Rostasy K, et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology. 2006 ; 67: 2063-2065
136. Waubant E, Mowry EM, Krupp L, et al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology. 2011 ; 76: 1989-1995
137. van der Mei IA, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ. 2003 ; 327: 316
138. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. J Am Med Assoc. 2006 ; 296: 2832-2838
139. Cantorna MT, Hayes CE. DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A. 1996 ; 93: 7861-7864
140. Garcion E, Sindji L, Nataf S, et al. Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. Acta Neuropathol. 2003 ; 105: 438-448
141. Mattner F, Smiroldo S, Galbiati F, et al. Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1,25-dihydroxyvitamin D3. Eur J Immunol. 2000 ; 30: 498-508
142. Meehan TF, DeLuca HF. The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D3 to suppress experimental autoimmune encephalomyelitis in mice. Arch Biochem Biophys. 2002 ; 408: 200-204
143. Meehan TF, DeLuca HF. CD8+ T cells are not necessary for 1 alpha,25-dihydroxyvitamin D3 to suppress experimental autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S Am. 2002 ; 99: 5557-5560
144. Nashold FE, Hoag KA, Goverman J, Hayes CE. Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D3 prevention of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2001 ; 119: 16-29
145. Nashold FE, Miller DJ. Hayes CE. 1,25-Dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2000 ; 103: 171-179
146. Nataf S, Garcion E. Darcy F, et al. 1,25 Dihydroxyvitamin D3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. J Neuropathol Exp Neurol. 1996 ; 55: 904-914
147. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol. 2005 ; 175: 4119-4126
148. Penna G, Amuchastegui S. Giarratana N, et al. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol. 2007 ; 178: 145-153
149. Adorini L, Penna G, Giarratana N, et al. Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J Steroid Biochem Mol Biol. 2004 ; 89-90: 437-441
150. Penna G. Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000 ; 164: 2405-2411
151. Griffin MD, Lutz W, Phan VA, et al. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A. 2001 ; 98: 6800-6805
152. Alroy I, Towers TL, Freedman LP. Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol. 1995 ; 15: 5789-5799
153. Muller K. Bendtzen K. 1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions. J Invest Dermatol Symp Proc. 1996 ; 1: 68-71
154. Muthian G, Raikwar HP, Rajasingh J, Bright JJ.. 1,25 Dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J Neurosci Res. 2006 ; 83: 1299-1309
155. Cohen-Lahav M, Douvdevani A, Chaimovitz C, Shany S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol. 2007 ; 103: 558-562
156. Koli K. Keski-Oja J. 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 2000 ; 11: 221-229
157. Rahman A, Hershey S, Ahmed S, et al. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol. 2007 ; 103: 416-419
158. Pedersen LB, Nashold FE, Spach KM. Hayes CE. 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res. 2007 ; 85: 2480-2490
159. Branisteanu DD, Waer M, Sobis H, et al. Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 alpha, 25-(OH)2D3. J Neuroimmunol. 1995 ; 61: 151-160
160. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses. 1986 ; 21: 193-200
161. Wingerchuk DM, Lesaux J, Rice GP, et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005 ; 76: 1294-1296
162. Niino M, Fukazawa T, Yabe I, et al. Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J Neurologic Sci. 2000 ; 177: 65-71
163. Tajouri L, Ovcaric M, Curtain R, et al. Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population. J Neurogenet. 2005 ; 19: 25-38
164. Partridge JM, Weatherby SJ, Woolmore JA, et al. Susceptibility and outcome in MS: associations with polymorphisms in pigmentation-related genes. Neurology. 2004 ; 62: 2323-2325
165. Dickinson JL, Perera DI, van der Mei AF, et al. Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 vitamin D receptor variant in this interaction. Mult Scler. 2009 ; 15: 563-570
166. Ramagopalan SV, Maugeri NJ, Handunnetthi L, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 2009 ; 5: e1000369
167. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 2010 ; 67: 618-624
168. Mikaeloff Y, Caridade G, Tardieu M, Suissa S. Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain. 2007 ; 130 (pt 10). 2589-2595
169. Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology. 2009 ; 73: 1543-1550
170. Chitnis T, Tenembaum S, Banwell B, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012 ; 18: 116-127